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ProteasomeInositol 1,4,5-trisphosphate (IP3) receptors are endoplasmic reticulum (ER) membrane calcium channels
that, upon activation, become substrates for the ER-associated degradation (ERAD) pathway. While it is clear
that IP3 receptors are polyubiquitinated and are transferred to the proteasome by a p97-based complex,
currently very little is known about the proteins that initially select activated IP3 receptors for ERAD. Here,
we have transfected HeLa cells to stably express m3 muscarinic receptors to allow for the study of IP3
receptor ERAD in this cell type, and show that IP3 receptors are polyubiquitinated and then degraded by the
proteasome in response to carbachol, a muscarinic agonist. In seeking to identify proteins that mediate IP3
receptor ERAD we found that both SPFH1 and SPFH2 (also known as erlin 1 and erlin 2), which exist as a
hetero-oligomeric complex, rapidly associate with IP3 receptors in a manner that precedes polyubiquitina-
tion and the association of p97. Suppression of SPFH1 and SPFH2 expression by RNA interference markedly
inhibited carbachol-induced IP3 receptor polyubiquitination and degradation, but did not affect carbachol-
induced calcium mobilization or IκBα processing, indicating that the SPFH1/2 complex is a key player in IP3
receptor ERAD, acting at a step after IP3 receptor activation, but prior to IP3 receptor polyubiquitination.
Suppression of SPFH1 and SPFH2 expression had only slight effects on the turnover of some exogenous
model ERAD substrates, and had no effect on sterol-induced ERAD of endogenous 3-hydroxy-3-
methylglutaryl-CoA reductase. Overall, these studies show that m3 receptor-expressing HeLa cells are a
valuable system for studying IP3 receptor ERAD, and suggest that the SPFH1/2 complex is a factor that
selectively mediates the ERAD of activated IP3 receptors.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
The ubiquitin–proteasome pathway (UPP) provides the primary
route for proteolysis within cells and has two parts—the attachment of
polyubiquitin chains to selected proteins and the recognition and
degradation of these polyubiquitinated proteins by the proteasome, a
26S multi-subunit protease located in the cytosol and nucleus [1]. The
endoplasmic reticulum (ER)-associated degradation (ERAD) pathway
is a facet of the UPP responsible for the degradation of aberrant
proteins in the ER [1]. In addition to this “quality control” function, the
ERAD pathway also accounts for the elimination of certain metabol-
ically-regulated native ER membrane proteins, including inositol
1,4,5-trisphosphate (IP3) receptors (IP3Rs) [2] and 3-hydroxy-3-
methylglutaryl-CoA reductase (HMGR) [3].+1 315 464 8014.
iewicz).
ll rights reserved.IP3Rs form tetrameric, IP3- and Ca2+-gated Ca2+ channels in ER
membranes and play a key role in cell signaling [4]. Stimulation of
certain cell surface receptors triggers IP3 formation at the plasma
membrane, which then diffuses through the cytosol and binds to IP3Rs
[4]. This, in concert with Ca2+ binding, induces conformational
changes in the tetrameric channel that permit Ca2+ to ﬂow from
stores within the ER lumen into the cytosol [4]. There are three IP3R
types in mammals, IP3R1, IP3R2 and IP3R3, and while they differ
considerably in their tissue distribution, they have broadly similar
properties, are often co-expressed, and can form homo- or hetero-
tetramers [4]. Remarkably, G-protein-coupled receptor (GPCR)-
induced activation of endogenous IP3Rs can lead to their rapid
polyubiquitination and subsequent degradation by the proteasome
[2,5,6], a phenomenon that has been demonstrated in many
mammalian cell types, including gonadotropin-releasing hormone-
stimulated αT3-1 mouse pituitary gonadotropes [7], and endothelin
1-stimulated Rat-1 primary ﬁbroblasts [8]. The ERAD pathway seems
to be responsible for this process, as a ubiquitin-conjugating enzyme
Fig. 1. Characteristics of Ca2+ signaling and IP3R1 processing in mHeLa cells. (A)
Suspensions of HeLa andmHeLa cells were exposed to 1mM carbachol as indicated, and
cytosolic [Ca2+] was determined. (B) Monolayers of HeLa and mHeLa cells were
incubated as indicated with 10 μM carbachol for 1–4 h, without or with 1 h pre-
incubation with 10 μM bortezomib, lysates were prepared, and were probed in
immunoblots for IP3R1 and β-actin. (C) Monolayers of HeLa and mHeLa cells were
incubated as indicated with 10 μM carbachol in the absence or presence of 1 μM
thapsigargin (Tg) or 1 μM atropine (At), lysates were prepared, and were incubated
with anti-IP3R1, and immunoprecipitates were probed for ubiquitin (upper panel) and
IP3R1 (lower panel).
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ERAD [1,3], and the p97–Ufd1–Npl4 complex, which is known to
facilitate the extraction of ERAD substrates from the ER membrane
[1,3], also mediates the degradation of polyubiquitinated IP3Rs [10].
Importantly, endogenous IP3Rs represent a unique tool for studying
ERAD, since activation almost instantaneously converts them from
stable, native proteins into ERAD substrates [2,7,10].
Here, we sought to establish a HeLa cell-based system for the study
of IP3R ERAD, since HeLa cells are very amenable to transient
transfection with exogenous constructs, including those that mediate
RNA interference [11,12]. To this end, we transfected HeLa cells to
stably express m3 muscarinic receptors and found that activation of
those muscarinic receptors with carbachol did indeed elicit IP3R
ERAD. Further, in seeking to deﬁne the proteins that mediate IP3R
ERAD we found that two partially characterized proteins, SPFH1 and
SPFH2 (also known as erlin-1 and erlin-2) [13,14], which exist as a
heteroligomeric complex, rapidly associate with IP3 receptors in a
manner that precedes polyubiquitination, and mediate IP3 receptor
ERAD. Our data suggest that the SPFH1/2 complex is a factor that
selectively targets activated IP3 receptors for ERAD.
2. Experimental procedures
2.1. Cells
HeLa cells were cultured in Dulbecco's modiﬁed Eagle's medium
supplemented with 5% fetal bovine serum, 100 units/mL penicillin
and 100 μg/mL streptomycin. mHeLa cells were prepared by
transfecting HeLa cells with a pcDNA3.1+-based plasmid encoding
human m3 muscarinic acetylcholine receptor tagged at the N-
terminus with 3 hemagglutinin (HA) epitopes (UMR cDNA Resource
Center). In brief, 105 HeLa cells were transfected with 2 μg PvuI-
linearized plasmid/3 μl LipoFectamine2000 (Invitrogen), were sub-
cultured into 96-well plates, and were grown for 14–20 days in
culture medium containing 1.3 mg/ml G418 to obtain single G418-
resistant clones. The clone (M4) expressing the highest m3 musca-
rinic receptor levels (as assessed by HA-epitope immunoreactivity)
was selected for further study, was maintained in medium containing
300 μg/ml G418, and was subcultured in G418-free medium prior to
experiments.
2.2. Materials
Antibodies used were: rabbit polyclonal anti-IP3R1 [6], anti-SPFH2
[15] and anti-HMGR membrane region [16], rat monoclonal anti-
grp94 (StressGen), and mouse monoclonal anti-ubiquitin clone FK2
(Bio-Mol International) or clone P4D1 (Santa Cruz Biotechnology),
anti-HMGR clone A9 (ATCC), anti-β-actin (Sigma), anti-p97 (Re-
search Diagnostics, Inc.), anti-IκBα (BD Transduction Laboratories),
anti-GFP (Roche Diagnostics), and anti-SPFH1 (a gift from Dr Stephen
Robbins; clone 10E6 being used for immunoprecipitations and clone
7D3 being used for immunoblotting) [13]. Triton X-100, puromycin,
cycloheximide (CHX), protease inhibitors, cholesterol, N-ethylmalei-
mide (NEM), carbachol, and tumor necrosis factor α (TNFα) were
purchased from Sigma; MG-132 was from Calbiochem; mevalonate
was from Fluka; 25-hydroxycholesterol was from Steraloids; G418
was from Invitrogen; and Protein A-Sepharose CL-4B was from
Amersham Biosciences. Bortezomib was a gift from Millennium
Pharmaceuticals, and compactin was a gift from Dr. Robert Simoni.
Lipoprotein-deﬁcient fetal calf serum (LPDS) was prepared as
described [17].
2.3. IP3R down-regulation and polyubiquitination
For down-regulation experiments (Fig. 1B), mHeLa cells were
seeded at 5×105 cells/well in 6-well plates, were incubated in culturemedium with stimuli, were detached with 155 mM NaCl, 10 mM
HEPES, 1 mM EDTA, pH 7.4 (HBSE), were centrifuged (16,000×g for
1 min at 25 °C), were solubilized for 30 min at 4 °C with ∼100 μl lysis
buffer (150 mM NaCl, 50 mM Tris-HCl, 1 mM EDTA, 1% Triton X-100,
pH 8.0) supplemented with a protease inhibitor cocktail (0.2 mM
phenylmethylsulfonyl ﬂuoride, 10 μM leupeptin, 10 μM pepstatin,
0.2 μM soybean trypsin inhibitor) and 1 mM DTT, were centrifuged
(16,000×g for 10 min at 4 °C), and samples were mixed with gel
loading buffer for electrophoresis and immunoblotting [6,15]. For
polyubiquitination/co-immunoprecipitation experiments (Figs. 1C
Fig. 2. SPFH1 and SPFH2 rapidly associate with activated IP3Rs (A) Monolayers of
mHeLa cells were treated with 10 μM carbachol for the times indicated, lysates were
incubated with anti-IP3R1, and immunoprecipitates were probed for ubiquitin, p97,
SPFH1, SPFH2 and grp94 (lanes 1–8) together with cell lysate (lane 9). (B) mHeLa cell
lysates were probed with anti-SPFH1 (lane 1), anti-SPFH2 (lane 2), or with both
antisera together (lane 3).
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incubated in culture medium with stimuli and were solubilized by
the addition of lysis buffer plus protease inhibitor cocktail. Lysates
were then treated with 2.5 mM NEM for 1 min to inhibit
deubiquitinating enzymes, followed by 5 mM DTT. After 30 min at
4 °C, lysates were centrifuged (16,000×g for 10 min at 4 °C) and
IP3R1 was immunoprecipitated by incubating with anti-IP3R1 and
Protein A-Sepharose CL-4B for 6–16 h at 4 °C. Immunoprecipitates
were washed thoroughly with lysis buffer (1000×g for 1 min at 4 °C)
and resuspended in gel loading buffer for subsequent electrophoresis
and immunoblotting [6,15].
2.4. RNA interference in mHeLa cells
Short interfering RNA (siRNA) sequences against human SPFH2
mRNA (SPFH2si1 and SPFH2si5) and a control siRNA (Random), have
been described previously [15]. These and two siRNAs designed
against human SPFH1 mRNA, encoded by TCCCAGAAGCCATAAGAAG
(SPFH1si2) and GTACCAGGCCATTGCTTCT (SPFH1si4), and which
were equally effective, were expressed from pSUPER.retro.puro vec-
tors [15]. To measure effects of RNA interference on IP3R1 and HMGR
down-regulation, IP3R1 polyubiquitination, or IκBα processing, mHeLa
cells were seeded, respectively, in 6-well plates (2×105/well), 10 cm
diameter dishes (12×106/dish) or 12-well plates (105/well) in
antibiotic-free medium, and 24 h later were transiently transfected
using LipoFectamine2000 and pSUPER.retro.puro vectors in the ratios
6 μl/2.4 μg, 34 μl/14 μg, and 3 μl/1.2 μg. After 24 h, the medium was
replaced withmedium supplemented with puromycin (1 μg/ml) to kill
non-transfected cells, 24 h later medium was changed, and 24 h latercells were stimulated and lysates were prepared and processed as
already indicated. To facilitate HMGR analysis (Fig. 7A), this enzyme
was up-regulated prior to cell stimulation by incubation for 24 h in
medium supplemented with 5% (v/v) LPDS, 2 μM compactin and
100 μM mevalonate [17]. In restoration experiments (Fig. 4A, lanes
6–9), cells were transfected 24 h prior to stimulation with a mouse
SPFH2 cDNA construct (SPFH2-5⁎; 34 μl LipoFectamine2000/14 μg
cDNA) that contains silentmutations that render themRNA resistant to
SPFH2si5 [15].
2.5. Calcium measurements
Cytosolic Ca2+ concentration in cell suspensions was measured by
loading cells with 10 μM Fura2-AM for 30 min at 37 °C as described
[8]. Imaging of adherent single cells was achieved using a Till
Photonics Polychrome V to generate 340 and 380 nm light, an
Olympus IX71 inverted microscope ﬁtted with a UApo/340, 40×, 1.35
numerical aperture oil immersion objective, an Imago-QE camera to
capture images, and Tillvision software to run experiments. Cells
(2×105) on 25 mm glass cover slips were rinsed three times and
incubated in Krebs-HEPES buffer [8] with 5 μM Fura2-AM for 45 min
at 37 °C, were rinsed three times, were incubated for 10 min at 37 °C,
and ﬁnally were perfused on the microscope stage at 37 °C with
Krebs-HEPES buffer.
2.6. Analysis of model ERAD substrates
GFPu is an unstable variant of EGFP created by fusing the CL1
degron to its C-terminus [18]. The other substrates used were TCRα, a
transmembrane subunit of the T-cell receptor complex [19], and two
terminally misfolded, ER luminal proteins, the glycosylated null Hong
Kong variant of α1-antitrypsin (A1AT-NHK) [20] and the nonglyco-
sylated transthyretin D18G mutant (TTR-D18G) [21]. GFP tags were
added by fusing EGFP cDNA to the 3′ end of substrate cDNAs and
insertion into pcDNA3.1+ as described [22]. HEK cells stably ex-
pressing GFPu, TCRα-GFP, A1AT-NHK-GFP or TTR-D18G-GFP [22]
were transiently transfected using Fugene 6 (Roche) with pSUPER-
STAR constructs encoding SPFH1si2 and SPFH2si5, or siRNAs against
S2, or Hrd1 (encoded by GAAACATTATTCTAGGCAA and GAGACAG-
TTTCAGATGATT, respectively). The constructs also encode a truncated
CD4 cell surface marker to facilitate detection and analysis of trans-
fected cells [22]. 72 h later, cells in suspension were labeled with
allophycocyanin-conjugated anti-CD4 (Invitrogen), and a FACSCalibur
ﬂow cytometer (Becton Dickson) was employed to measure GFP
ﬂuorescence levels for ∼20,000 CD4+ cells as previously described
[22]. Mean GFP ﬂuorescence in CD4+ cells was determined and
normalized to the levels in Random shRNA-expressing cells for three
independent experiments. The turnover of these substrates in HeLa
cells was examined by transiently co-transfecting cells in 24-well
plates (plated 24 h earlier at 5×104 cells/well) with cDNAs encoding
the GFP-tagged substrates in pcDNA3.1+ together with SPFH1si4 plus
SPFH2si7 (encoded by GTACAAGGCCATTGCTTCC) in 6OH1OpSUPER.
retro.puro, selecting for shRNA-expressing cells with 1 μg/mL
puromycin, and 72 h later, measuring substrate levels with anti-GFP
as described [15].
2.7. Analysis of HMGR processing
Random or SPFH1si4 plus SPFH2si6 siRNAs were expressed in Rat1
cells from the doxycycline-regulated 6OH1O-pSUPER.retro.puro vec-
tor as described [23]. Endogenous HMGR levels were upregulated by
incubating the cells for 12–16 h in DMEM supplemented with 10%
(v/v) LPDS, 2 μM compactin and 100 μM mevalonate. Metabolic
labeling with [35S]-methionine/cysteine, immunoprecipitation, and
immunoprobing for polyubiquitinated HMGR or unmodiﬁed HMGR
were carried out as previously described [16,24,25].
Fig. 3. SPFH1 and SPFH2 form a high molecular mass complex. (A) mHeLa cell lysates
were subjected to blue-native PAGE as described [34] and were probed with the
antibodies indicated. The molecular mass markers and the migration positions of p97
and IP3R1 (which are hexameric and tetrameric, respectively) indicate that SPFH1 and
SPFH2 form a large complex. (B) mHeLa cell lysates were incubated without antibody
(lane 1), or with anti-SPFH1 (lane 2), or anti-SPFH2 (lane 3) and immunoprecipitates
and the immunodepleted cell lysates were probed for SPFH1 and SPFH2.
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All experiments were repeated at least once, and representative
images of gels, micrographs or Ca2+ traces are shown. Immunoreac-
tivity was quantitated using a Genegnome Imager (Syngene BioIma-
ging) and are graphed as mean±SEM of n independent experiments.
Routinely (e.g. for SPFH2), quantitation was of discrete bands of a
speciﬁc size, while for polyubiquitinated IP3R1, ubiquitin immuno-
reactivity in the 270–380 kDa region of gels was assessed.
3. Results
3.1. IP3R1 processing in mHeLa cells
mHeLa cells were prepared by stable transfection of HeLa cells
with a vector encoding HA-tagged human m3-muscarinic receptor.
Exposure of mHeLa cells to the muscarinic receptor agonist carbachol
caused a rapid and sustained elevation of cytosolic Ca2+ concentration
that was not seen in unmodiﬁed HeLa cells (Fig. 1A), indicating that
the exogenous m3 receptors couple appropriately to IP3 production,
IP3R activation and Ca2+ mobilization [4].
The experimental hallmarks of GPCR-induced IP3R ERAD are that
proteasome inhibitors block IP3R degradation, and that in the absence
of proteasome inhibitors, only a small fraction of IP3Rs (b10%) can be
seen to be polyubiquitinated, because polyubiquitinated IP3Rs are
rapidly degraded by the proteasome [2,7]. This was the case in
carbachol-stimulated mHeLa cells. Fig. 1B shows that IP3R1 was
down-regulated ∼50% by carbachol treatment of mHeLa cells with
half-maximal effect at ∼1.5 h (lanes 3–7). This effect was blocked by
the proteasome inhibitor bortezomib (lanes 8–12), and was not seen
in unmodiﬁed HeLa cells (lanes 1–2). Similar results were seen for
IP3R3 (not shown), which together with IP3R1, makes up the vast
majority of the IP3R complement of HeLa cells [26], and mHeLa cells
(not shown). Fig. 1C upper panel shows that in mHeLa cells (lanes 3–
10), but not in unmodiﬁed HeLa cells (lanes 1–2), carbachol increased
IP3R1 polyubiquitination, peaking at ∼20 min. That IP3R1 immuno-
reactivity (lower panel) was not clearly smeared upwards is
consistent with only a small fraction of IP3Rs being polyubiquitinated.
Fig. 1C also shows that carbachol-induced IP3R1 polyubiquitination
was blocked by co-incubation with the muscarinic receptor antago-
nist atropine (lane 12), indicating that the effects of carbachol are
mediated by the exogenous m3 receptors. Likewise, thapsigargin,
which inhibits ER Ca2+-ATPase and depletes ER Ca2+ stores in HeLa
cells [26], was inhibitory (lane 11). This is also a hallmark of IP3R
ERAD, presumably because intact Ca2+ stores are needed for the
events that trigger IP3R polyubiquitination [10]. Overall, these data
show that the processing of IP3Rs in mHeLa cells is essentially
identical to that seen in other cells types in which endogenous GPCRs
are used to initiate IP3R ERAD. It is interesting to note, however, that
under resting conditions, IP3R1 levels in mHeLa cells were less than
that seen in HeLa cells (Fig. 1B, compare lanes 1 and 3) and IP3R1
polyubiquitination was slightly more pronounced (Fig. 1C, compare
lanes 1 and 3). This suggests that some IP3R ERADmay be occurring in
resting mHeLa cells, perhaps because the exogenous muscarinic
receptors can slightly elevate basal IP3 levels even in the absence of
stimulus.
3.2. SPFH1 and SPFH2 associate with activated IP3Rs
The known capacity of proteins that mediate ERAD (e.g. p97) to
associate with activated IP3Rs in αT3-1 and Rat 1 cells [8,15,23],
motivated us to examine whether p97, and perhaps additional
mediators, might associate with activated IP3Rs in mHeLa cells. To
study the association dynamics of these proteins with activated
IP3R1, we stimulated mHeLa cells with carbachol for various times,
immunoprecipitated IP3R1, and probed immunoblots for a variety ofproteins (Fig. 2A). p97 co-immunoprecipitated with IP3R1 in a
manner that slightly lagged behind IP3R1 polyubiquitination,
peaking at 20–30 min. As p97, and its cofactors Ufd1 and Npl4,
directly bind to ubiquitin [1,3,27], this interaction of p97 with
activated IP3Rs could well be via attached ubiquitin moieties. We
also probed for SPFH1 and SPFH2. These ∼340 amino acid proteins
are closely related (73% identical and 91% similar) [13,14,23] and
share homology with a diverse family of proteins that contain an
SPFH domain, an ∼200 amino acid motif of unknown function,
named for the original family members: Stomatin, Prohibitin, Flo-
tillin, and HﬂC/HﬂK [14]. Interestingly, SPFH1 and SPFH2 have also
recently been reported to be components of detergent-resistant
membranes derived from the ER [13] and to associate with IP3Rs in
stimulated αT3-1 and Rat-1 cells [15,23]. In mHeLa cells, the peak
interaction of SPFH1 and SPFH2 with IP3R1 occurred prior to peak
polyubiquitination, and both were strongly associated with IP3R1 as
little as 1 min after carbachol addition (Fig. 2A). Fig. 2B veriﬁes that
anti-SPFH1 and anti-SPFH2 are speciﬁc to their intended targets,
recognizing proteins at ∼41 kDa and ∼43 kDa, respectively. Probing
for grp94 served as a negative control; this ER luminal protein did
not co-immunoprecipitate with IP3R1 at all after carbachol addition
(Fig. 2A).
It has recently been shown that SPFH1 and SPFH2 associate into
hetero-oligomeric ∼1 MDa complexes [23,28]. This was also the case
in mHeLa cells, since both proteins migrated at ∼1 MDa under non-
denaturing conditions (Fig. 3A, lanes 1 and 2), and anti-SPFH2 immu-
noprecipitated and immunodepleted both SPFH2 and SPFH1 from cell
lysates (Fig. 3B, lane 3), as did anti-SPFH1 (lane 2), albeit less effec-
tively than anti-SPFH2, due to anti-SPFH1 being relatively ineffective
at immunoprecipitating. Overall, these data indicate that in mHeLa
cells, a complex composed of SPFH1 and SPFH2 binds to IP3R1s as soon
as they are activated and prior to their polyubiquitination.
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In order to investigate the roles of SPFH1 and SPFH2 we used RNA
interference to “knock down” each protein. On average (n=6), SPFH1
siRNA reduced SPFH1 immunoreactivity by 87±2%without inhibiting
SPFH2 levels (e.g. Fig. 4B, lane 4), while SPFH2 siRNA reduced SPFH2
immunoreactivity by 80±5% and surprisingly also reduced SPFH1
immunoreactivity by 40±6% (e.g. Fig. 4B, lane 7). When the siRNAs
were combined, SPFH1 and SPFH2 immunoreactivities were reduced
by 88±2% and 78±6%, respectively (e.g. Fig. 4B, lane 10). Why the
SPFH2 siRNA also affects SPFH1 levels is presently unclear, but maybe
because it weakly targets SPFH1 mRNA. SPFH2 siRNA strongly inhi-
bited carbachol-induced IP3R1 polyubiquitination (Fig. 4A, lane 4) and
down-regulation (Fig. 4B, lanes 7–9) and clearly elevated resting IP3R1
levels (Fig. 4B, compare lanes 1 and 7). SPFH1 siRNA had similar but
less pronounced effects on IP3R1 polyubiquitination (Fig. 4A, lane 3)
and down-regulation (Fig. 4B, lanes 4–6), and the siRNAs in
combination were not substantially more effective than SPFH2 siRNA
alone (Fig. 4A, lane 5 and Fig. 4B, lanes 10–12). Overall, these data are
consistent with recent studies in Rat1 cells in which both SPFH1 and
SPFH2 siRNAs strongly inhibited IP3R1 processing [23]. The greater
effectiveness of SPFH2 siRNA seen in the present study likely results
from the fact that, in mHeLa cells, SPFH2 siRNA depletes both SPFH1
and SPFH2, while SPFH1 siRNA depletes only SPFH1. Intriguingly,
SPFH1 knockdown reduced co-immunoprecipitation of SPFH2 with
IP3R1 (Fig. 4A, lane 3), and vice versa (lane 4), indicating again that it is
the complex formed by these proteins that binds to activated IP3Rs.Fig. 4. SPFH1 and/or SPFH2 knockdown inhibits the polyubiquitination and degradation o
(lanes 1, 2, 6 and 7), or SPFH1si2 and/or SPFH2si1 plus SPFH2si5 siRNAs (lanes 3–5), or SP
carbachol for the times indicated. In restoration experiments (lanes 6–9), cells were transfec
exogenous SPFH2. Cell lysates were then prepared and were incubated with anti-IP3R1, and i
Cell lysates were also probed for SPFH1, SPFH2 and β-actin (lower panels), to reveal the exten
and 9). (B) mHeLa cells were transfected with vectors and exposed to carbachol as in A lan
Quantitated data are graphed in the lowest panel (n≥4, ⁎pb0.05).Importantly, the data shown in Fig. 4 could be replicated when siRNAs
targeting other SPFH1 and SPFH2 mRNA sequences were used (data
not shown), indicating that “off-target” effects are not responsible for
the inhibition of IP3R1 processing. Further, reintroduction of exoge-
nous SPFH2 by transient transfection into mHeLa cells in which endo-
genous SPFH2 was depleted by RNA interference partially reversed
inhibition of IP3R1 polyubiquitination (Fig. 4A, lanes 6–9); most likely
the restoration is incomplete because transient transfection does not
cause the expression of exogenous SPFH2 in all cells (data not shown).
Overall, since knockdown of SPFH1 and/or SPFH2 inhibits IP3R1
polyubiquitination, it appears that the complex formed by these
proteins somehow mediates this event. As IP3R polyubiquitination
requires that IP3Rs can be activated normally [10] it is a formal
possibility that the inhibitory effect of SPFH1 and/or SPFH2 knock-
downcould result from inhibition of IP3R activation. However, thiswas
not the case, as Ca2+ mobilization in response to carbachol was
unaffected by SPFH1 and 2 knockdown (Fig. 5A).
To further examine the speciﬁcity of the functions of the SPFH1/2
complex, we examined the processing of IκBα, a cytosolic protein that
is rapidly degraded via the UPP, but independently of ERAD [29]. In
HeLa cells, TNFα has been shown previously to stimulate IκBα
polyubiquitination and degradation, with proteasome inhibitors
causing the accumulation of polyubiquitinated species and blocking
IκBα degradation [29,30]. These events were not inhibited by SPFH1
and 2 knockdown in mHeLa cells (Fig. 5B, compare lanes 3 and 4, with
9 and 10). Remarkably, muscarinic receptor activation also caused
IκBα polyubiquitination and degradation, albeit to a lesser extent thanf IP3Rs. (A) mHeLa cells were transfected with vectors encoding either Random siRNA
FH2si5 siRNA only (lanes 8–9) and 72 h later were incubated without or with 10 μM
ted 24 h prior to carbachol treatment with either empty vector or a construct encoding
mmunoprecipitates were probed for ubiquitin, IP3R1, SPFH1 and SPFH2 (upper panels).
t of SPFH1 and SPFH2 knockdown and exogenous SPFH2 expression (asterisks in lanes 7
es 1–5 and cell lysates were prepared and probed for IP3R1, SPFH1, SPFH2 and β-actin.
Fig. 5. SPFH1 and SPFH2 knockdown does not alter Ca2+ signaling or the
polyubiquitination of IκBα. mHeLa cells were transfected as in Fig. 4 and 72 h later
were incubated without or with the stimuli indicated. (A) The 340/380 nm ratio (an
index of [Ca2+]) was measured in individual cells attached to cover slips during
perfusion without or with 10 μM carbachol (solid bar) and data from four cells for each
condition were averaged. The inset shows the levels of SPFH1 (upper panel) and SPFH2
(lower panel) under each condition. (B) Cells were treated with 2 ng/ml TNFα or 1 mM
carbachol for 30 min, without (−) or with (+) a 30 min pre-incubation with 1 μM
bortezomib, and cell lysates were probed for IκBα, SPFH2, SPFH1 and β-actin. The graph
shows data from time-courses in which IκBα immunoreactivity at ∼37 kDa in the
absence of bortezomib was quantitated.
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down (Fig. 5B, compare lanes 5 and 6, with 11 and 12). Graphing the
time course of IκBα degradation (Fig. 5C) conﬁrmed the lack of effect
of SPFH1 and 2 knockdown, but also revealed that SPFH1 and 2
knockdown caused a slight (∼10%) reduction in IκBα levels, even in
the absence of stimulus, the reason for which is presently unclear.
Overall, Fig. 5 shows that the inhibitory effects of SPFH1 and 2knockdown on IP3R processing in mHeLa cells are not due to a general
perturbation of the UPP or inhibition of m3 receptor function.
3.4. Effects of SPFH1 and SPFH2 knockdown on the stability of model
ERAD substrates and HMGR
To examine whether the SPFH1/2 complex is speciﬁc for IP3Rs, or
plays a more general role in ERAD, we initially assessed the effects of
SPFH1 and SPFH2 depletion on the degradation of several GFP-tagged
“model” ERAD substrates: TCRα [19], A1AT-NHK [20] and TTR-D18G
[21]. Steady-state GFP ﬂuorescence in cells expressing these proteins
reﬂects the balance between the their synthesis and degradation, and
a degradation defect results in increased GFP ﬂuorescence, which can
be readily measured by ﬂow cytometry [22]. Depletion of SPFH1 and
SPFH2 in HEK cells had a slight but signiﬁcant effect on the steady-
state levels of A1AT-NHK-GFP and TTR-D18G-GFP, but not of TCRα-
GFP or GFPu, a cytosolic UPP substrate (Fig. 6A) [18]. In contrast,
depletion of the ERAD ubiquitin ligase Hrd1 [3] or the S2 subunit of
the proteasome [1] stabilized all four substrates, albeit to different
extents, indicating that they have different processing requirements.
Knockdown of SPFH1 and SPFH2 also slightly increased the basal
levels of A1AT-NHK-GFP and TTR-D18G-GFP (but not TCRα-GFP)
when expressed in HeLa cells (Fig. 6B), and slightly inhibited their
degradation rates measured after CHX addition (Fig. 6B). Thus, the
SPFH1/2 complex regulates the stability of certain ERAD substrates
(A1AT-NHK-GFP and TTR-D18G-GFP), although the effect of SPFH1/2
depletion on these substrates is less pronounced than that seen for
activated IP3Rs (Fig. 4B, lowest panel). Possible explanations for this
difference are that the SPFH1/2 complexes that remain after RNAi are
better able to support the ERAD of exogenous model substrates than
endogenous IP3Rs, or that exogenous model substrates can undergo
degradation via multiple routes, only one of which is mediated by the
SPFH1/2 complex.
Finally, we examined whether sterol-induced ERAD of HMGR
[3,25] in mHeLa cells requires SPFH1 and 2 (Fig. 7A). Sterols
effectively down-regulated HMGR levels, but this was unaffected by
SPFH1 and 2 knockdown (lanes 1–6, and graph i), while under exactly
the same experimental conditions, carbachol-induced IP3R1 down-
regulation was blocked by SPFH1 and 2 knockdown (lanes 7–12, and
graph iv). Additional controls showed that sterols did not cause IP3R1
down-regulation (lanes 1–6 and graph iii) and that carbachol did not
cause HMGR down-regulation (lanes 7–12 and graph ii). Thus, SPFH1
and 2 do not mediate sterol-induced HMGR ERAD in mHeLa cells. We
also examined Rat1 cells in which we have found sterols to cause a
profound increase in endogenous HMGR ubiquitination (Fig. 7B) and
degradation (Fig. 7C), and in which SPFH1 and 2 can be effectively
depleted by RNA interference (Fig. 7B, lowest panels). However,
sterol-induced HMGR ubiquitination (Fig. 7B) and degradation (Fig.
7C) were unaffected by SPFH1 and 2 depletion, conﬁrming that the
SPFH1/2 complex is not involved in HMGR processing. In contrast, in
these same cells, SPFH1 and 2 depletion almost completely blocks the
ERAD of activated IP3Rs [23].
4. Discussion
The mechanism by which activated IP3Rs are degraded by the
ERAD pathway remains largely undeﬁned. We have begun to identify
the proteins that mediate this process using virally transduced Rat-1
cell cultures stably expressing exogenous siRNAs [8,15,23], but more
rapid screening of siRNAs has been hampered by the fact that Rat-1
cells exhibit low transfection efﬁciency in transient transfection
studies [8]. To accelerate this work we sought a cell line in which
IP3R ERAD can be measured that is also amenable to transient trans-
fection with siRNA-expressing vectors, and chose to use HeLa cells,
since these cells are known to be excellent recipients of transiently-
introduced siRNAs [11,12]. However, preliminary studies (not shown)
Fig. 6. SPFH1 and SPFH2 knockdown stabilizes certain model ERAD substrates. (A) HEK cells stably expressing GFPu, TCRα-GFP, A1AT-NHK-GFP or TTR-D18G-GFP were transfected
with vectors encoding random siRNA or SPFH1si2 plus SPFH2si5 siRNAs and the GFP ﬂuorescence of CD4+ cells was measured by ﬂow cytometry. Data were normalized to levels in
Random siRNA-expressing cells and graphed as the fold change inmean GFP ﬂuorescence (n=3, ⁎pb0.05). (B) HeLa cells were co-transfected with cDNA encoding TCRα-GFP, A1AT-
NHK-GFP or TTR-D18G-GFP together with vectors encoding Random siRNA or SPFH1si4 plus SPFH2si7 siRNAs, were treated with 20 μg/mL CHX for the indicated times, and cell
lysates were probed for the indicated proteins. Quantitated data are graphed (n≥7, ⁎pb0.05).
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capable of eliciting IP3R ERAD, and thus we chose to introduce m3
muscarinic receptors, since these have been shown to initiate IP3R
ERAD in other cell types [31]. We found that introduction of m3
receptors allowed for robust carbachol-induced increases in cytosolic
Ca2+ concentration, IP3R1 polyubiquitination and IP3R1 down-
regulation with characteristics similar to that seen in other cell types.
Carbachol also caused the rapid association of SPFH1 and SPFH2
with activated IP3Rs, and the less rapid association of p97. SPFH1 and
SPFH2 are closely related proteins, that contain an N-terminal
transmembrane domain that targets the proteins to the ERmembrane
and a C-terminal region, including the SPFH domain, in the ER lumen[13–15,23,28]. Intriguingly, SPFH domain-containing proteins are
often found in large oligomeric structures [14], and this has recently
also been shown to be the case for SPFH1 and 2 [23,28]. mHeLa cell
SPFH1 and 2 were also found in high molecular mass complexes, and
it seems very likely that it is these complexes that are associating with
activated IP3Rs.
Knockdown of SPFH1 and/or SPFH2 in mHeLa cells inhibited
carbachol-induced IP3R1 polyubiquitination and down-regulation
and also elevated basal IP3R1 levels, pointing towards a role for
the SPFH1/2 complex in IP3R processing. Importantly, SPFH1 and 2
knockdown did not affect Ca2+ signaling via IP3Rs, demonstrating that
the locus of action of the complex is down-stream of IP3R activation.
Fig. 7. SPFH1 and SPFH2 knockdown does not affect the ubiquitination or degradation of HMGR. (A) mHeLa cells were transfected with siRNA-encoding vectors as in Fig. 4A lanes 1–
5, HMGR was up-regulated for 24 h, and cells were incubated with either sterols (2 μg/ml 25-hydroxycholesterol plus 20 μg/ml cholesterol) or carbachol (10 μM) as indicated. Cell
lysates were then prepared and were probed for HMGR (with A9), IP3R1, SPFH1, SPFH2 and β-actin. Quantitated HMGR and IP3R1 immunoreactivities are shown in graphs i–iv. (B)
Rat1 cells were induced with 1 μg/ml doxycycline to express either random or SPFH1/2 siRNAs [23], HMGR was up-regulated for 16 h, and cells were treated for 1 h with 5 μMMG-
132 without (−) or with (+) sterols, as indicated. Lysates were then incubated with anti-HMGR membrane region and immunoprecipitates were probed with anti-ubiquitin clone
P4D1 or anti-HMGR clone A9. Aliquots of cell lysates were probed with anti-SPFH1 and anti-SPFH2 to assess knockdown (lowest panels). (C) Rat1 cells were pretreated as in B and
were pulse-labeled for 30 min with [35S]-methionine/cysteine and chased in the absence or presence of sterols for the indicated times. Lysates were then incubated with anti-HMGR
membrane region and radioactivity of immunoprecipitated HMGR was assessed.
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cell cultures in which SPFH1 and 2 knockdown also inhibited IP3R
polyubiquitination and down-regulation [23]. This leads us to spe-
culate that the SPFH1/2 complex is a factor that recognizes activated
IP3Rs as potential ERAD substrates and triggers their polyubiquitina-
tion. The recognition site could be the large intraluminal loop between
the ﬁfth and sixth transmembrane domains of IP3Rs [4], since the bulk
of SPFH1 and 2 appear to reside in the ER lumen [13–15,23], and this
loop is already known to mediate interactions between IP3R1 and
other proteins [4].
Is the SPFH1/2 complex a speciﬁc mediator of IP3R ERAD, or does it
have a more general role in ERAD ? Support for the latter viewpoint
has come from studies showing that certain ERAD pathway com-
ponents (e.g. p97 and derlin1) co-purify with the SPFH1/2 complex
[15], and that certain exogenous model ERAD substrates (e.g. CD3δ)
are slightly stabilized by SPFH2 knockdown [15]. Additionally, SPFH1
and SPFH2 bind to certain proteins undergoing ERAD, including
CFTRΔF508 [32] and the α1D-adrenergic receptor [33]. However, the
data shown herein indicate that not all ERAD substrates are affected
by SPFH1 and SPFH2 knockdown, and that those that are affected
(A1AT-NHK-GFP and TTR-D18G-GFP), are stabilized only slightly and
much less than that seen after knockdown of Hrd1 or the S2 protea-some subunit, which are key ERAD pathway components [1,3]. This
indicates that the SPFH1/2 complex is not a central component of the
mammalian ERAD pathway. Further, sterol-induced ubiquitination
and degradation of endogenous HMGR is completely unaffected by
knockdown of SPFH1 and SPFH2, showing that the processing of this
substrate, which requires recognition by INSIGs [3], does not involve
the SPFH1/2 complex. Thus, while the SPFH1/2 complex is required
for IP3R ERAD and contributes slightly to the degradation of certain
model ERAD substrates, it is not essential for the processing of all
ERAD substrates in mammalian cells, and is most likely an ERAD
recognition factor with selectivity towards activated IP3Rs.
In summary, we have developed a HeLa cell line (mHeLa cells)
in which it is possible to study IP3R ERAD and have found, using
immunoprecipitation and RNAi, that the SPFH1/2 complex mediates
this process. The amenability of these cells to RNAi screening and
protein over-expression [12] should greatly facilitate examination of
the proteins that mediate IP3R ERAD.
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